Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
272 questions in 49 reviews · Heart
current versionsNo studies 272 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
[Radial] In‐plane B‐mode ultrasound vs out‐of‐plane B‐mode ultrasound Quality of life · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Doppler assistance vs palpation and landmarks Pseudoaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Doppler assistance vs palpation and landmarks Major haematoma · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Doppler assistance vs palpation and landmarks Adverse events (pain) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Doppler assistance vs palpation and landmarks Quality of life · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Dynamic out‐of‐plane B‐mode ultrasound vs static out‐of‐plane B‐mode ultrasound Pseudoaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Axillary] B‐mode ultrasound guidance vs palpation and landmarks Adverse events (pain) · adults requiring axillary artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Dynamic out‐of‐plane B‐mode ultrasound vs static out‐of‐plane B‐mode ultrasound Major haematoma · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Dynamic out‐of‐plane B‐mode ultrasound vs static out‐of‐plane B‐mode ultrasound Adverse events (pain) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Dynamic out‐of‐plane B‐mode ultrasound vs static out‐of‐plane B‐mode ultrasound Quality of life · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound Pseudoaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound Adverse events (pain) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Axillary] B‐mode ultrasound guidance vs palpation and landmarks Quality of life · adults requiring axillary artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound Quality of life · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Pseudoaneurysm · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
GLP‐1RA vs placebo Fracture · CVD (ASCVD, HF, or both) Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose… (2021) · Cochrane | no estimate extracted | NR | No studies |
High vs low alpha‐linolenic acid omega‐3 fats Harms: bleeding · adults with or without existing CVD Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease (2020) · Cochrane | no estimate extracted | NR | No studies |
High vs low omega‐3 fats Outcomes All in trials of 12 to 72 months' duration · adults with or without existing CVD Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Nifurtimox vs placebo Clinical improvement (N) · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Nifurtimox vs placebo Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Nifurtimox vs placebo Adverse events (N) · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Benznidazole vs placebo Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Benznidazole vs placebo Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Nifurtimox vs placebo Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Nifurtimox vs placebo Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) (2020) · Cochrane | no estimate extracted | NR | No studies |
Child nutrition education interventions vs no intervention Cost or cost effectiveness Not reported · children aged five years and under Interventions for increasing fruit and vegetable consumption in children aged five years and under (2020) · Cochrane | no estimate extracted | NR | No studies |
Child nutrition education interventions vs no intervention Unintended adverse events Not reported · children aged five years and under Interventions for increasing fruit and vegetable consumption in children aged five years and under (2020) · Cochrane | no estimate extracted | NR | No studies |
Child‐feeding interventions vs no intervention Cost effectiveness Short‐term impact (< 12 months) Not reported · children aged five years and under Interventions for increasing fruit and vegetable consumption in children aged five years and under (2020) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent interventions vs no intervention Cost effectiveness Short‐term impact (< 12 months) Not reported · children aged five years and under Interventions for increasing fruit and vegetable consumption in children aged five years and under (2020) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent interventions vs no intervention Unintended adverse events Short‐term impact (< 12 months) Not reported · children aged five years and under Interventions for increasing fruit and vegetable consumption in children aged five years and under (2020) · Cochrane | no estimate extracted | NR | No studies |
Dopexamine vs dopamine All‐cause long‐term mortality · adults with low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Milrinone vs dobutamine All‐cause mortality · adults with low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Enoximone vs dobutamine All‐cause long‐term mortality · adults with low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Dopamine‐milrinone vs dopamine‐dobutamine All‐cause long‐term mortality · adults with cardiogenic shock Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Enoximone vs piroximone All‐cause mortality · adults with low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Enoximone vs epinephrine‐nitroglycerine All‐cause mortality · adults with low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Levosimendan vs placebo All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Levosimendan vs enoximone All‐cause long‐term mortality · adults with cardiogenic shock Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Epinephrine vs norepinephrine‐dobutamine All‐cause long‐term mortality · adults with cardiogenic shock Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output… (2020) · Cochrane | no estimate extracted | NR | No studies |
Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) Adverse events1 · people with endocarditis caused by Staphylococcus aureus A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) Congestive heart failure1 · people with endocarditis caused by Staphylococcus aureus A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) Septic embolism1 · people with endocarditis caused by Staphylococcus aureus A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) Need for cardiac surgical interventions1 · people with endocarditis caused by Staphylococcus aureus A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) Uncontrolled infection1 · people with endocarditis caused by Staphylococcus aureus A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) Congestive heart failure · people with endocarditis due to Staphylococcus aureus in drug abusers A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) Septic embolism · people with endocarditis due to Staphylococcus aureus in drug abusers A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Levofloxacin vs standard treatment Cure4 · people with Staphylococcus aureus endocarditis A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) Need for cardiac surgical interventions · people with endocarditis due to Staphylococcus aureus in drug abusers A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) Uncontrolled infection · people with endocarditis due to Staphylococcus aureus in drug abusers A comparison of different antibiotic regimens for the treatment of infective endocarditis (2020) · Cochrane | no estimate extracted | NR | No studies |